Study Details
Testing the Drug Iptacopan in Pediatric Patients with Primary IgAN
(IRB#: IRB_00191700)
Primary IgAN is a chronic kidney disease. This study will test a drug called iptacopan to treat pediatric patients with this disease. The study wants to see if the drug will help people with the disease and is safe. People in the study will receive the treatment twice daily. Being in the study requires about 11 in-person study visits to the clinic over 15 months. Medical tests will be done during the study to track the health of participants. People will be paid for study participation.
- All genders
- All Ages
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: All Ages
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 2 to less than 18 years old at the start of the study
- Diagnosis of Primary IgAN
- Specific body weight measurement
- Supportive care with a stable dose of specific medication
- Able to attend in-person visits at the study clinic
Exclusion Criteria
- Current acute kidney injury (AKI)
- History or current diagnosis of clinically significant echocardiogram (heart) abnormalities
- Have had an organ transplant
- Major current health conditions, including heart disease
- Current use of herbal medications for IgAN, such as Lei Gong Teng
Will I be paid for my time?
Yes
IRB#: IRB_00191700
PI: Raoul Nelson
Department: PEDIATRICS
Approval Date: 2025-11-12 07:00:00
Specialties: Pediatric Nephrology
I am Interested